

Clinical Gastroenterology and Hepatology









Articles & Issues Collections Multimedia CME For Authors Journal Info AGA	
Search AGA Journals All Content	Advanced Search
< Previous Article Next Article >	Access this article on ScienceDirect
To read this article in full, please review your options for gaining access at the bottom of the page.	Article Tools
Article in Press	<u>PDF (1 MB)</u>
	Email Article
Rebleeding vs Thromboembolism After Hospitalization for	Add to My Reading List
•	Export Citation
Gastrointestinal Bleeding in Patients on Direct Oral	
Anticoagulants	Create Citation Alert
U	Cited by in Scopus (0)
Neil Sengupta, MD . Ariela L. Marshall, MD, Blake A. Jones, MD, Sandra Ham, MS, Elliot B. Tapper, MD	

Abstract

Background and Aims

Little is known about outcomes of patients hospitalized for gastrointestinal bleeding (GIB) while they are taking direct oral anticoagulants (DOAC). We aimed to determine the frequency at which patients resume DOAC therapy following hospitalization for GIB in a real-world setting, and the risks and benefits.

We conducted a retrospective analysis of medical claims data from the Truven Health Marketscan Commercial Claims and Encounters Database, from January 1, 2010 through December 31, 2014. We collected data on 1338 adults treated with DOACs and hospitalized for GIB (dabigatran, n=679; rivaroxaban, n=608, apixaban, n=51). Patients who developed GIB within 1 year of DOAC initiation, and had a DOAC claim filled within 1 month of GIB, were included in the analysis. Post-discharge readmissions due to thromboembolism and recurrent GIB within 90 days were reviewed. We used proportional hazards to identify factors associated with thromboembolism and recurrent GIB.

Results

The median age of patients who did not resume DOAC therapy was older (79 years vs 78 years for patients who did resume DOAC therapy; P=.0005). Higher proportions of patients who did not resume DOAC had heart failure (25% vs 20% who did resume DOAC therapy, P=.01), received blood (36% vs 24%; P<.0001), and required intensive care (18% vs 12%; P=.003). Restarting DOAC therapy within 30 days was not associated with thromboembolism within 90 days (hazard ratio [HR], 0.98; 95% CI, 0.37-2.21) or recurrent GIB (HR, 1.44; 95% CI 0.72–2.68). On multivariate regression, prior venous thromboembolism was associated with post-discharge thromboembolism (HR, 3.30; 95% CI, 1.29-7.38), and thienopyridine use was associated with recurrent GIB (HR, 3.12; 95% CI, 1.55-5.81). A higher proportion of patients who resumed treatment with rivaroxaban, compared to other DOACs, had recurrence of GIB (log rank, P=.04).

Conclusions

In a retrospective analysis of medical claims data from adults treated with DOACs and hospitalized for GIB, we found that older patients who require blood and intensive care were less likely to restart treatment with DOACs after GIB. Resuming DOAC therapy was not associated with thromboembolism within 90 days or recurrence of GIB; a history of venous thromboembolism and thienopyridine use were associated with risk of subsequent thromboembolism and GIB respectively

GI bleeding, anticoagulation, thromboembolism, outcomes

To access this article, please choose from the options below

Related Articles

Clinical Practice Guidelines for the Use of Video Capsule Endoscopy Gastroenterology, Vol. 152, Issue 3

American

Gastroenterological **Association Institute Technical** Review on the Management of **Acute Diverticulitis**

Gastroenterology, Vol. 149, Issue 7

Initial Medical Treatment of Acute Pancreatitis: American **Gastroenterological Association Institute Technical Review** Gastroenterology, Vol. 154, Issue 4

American

0 Gastroenterological


Association Technical Review on the Diagnosis and Management of Lynch Syndrome

Gastroenterology, Vol. 149, Issue 3

American Gastroenterological Association Institute Guideline on the Management of Acute **Diverticulitis**

Gastroenterology, Vol. 149, Issue 7

Ø 0



Financial Support: The authors report no financial or grant support for this project

Disclosures: The authors have no conflict of interest to declare

Authors Contributions: Sengupta N designed the study. Sengupta N, Jones B, Ham S collected clinical data. Sengupta N and Ham S conducted statistical analysis. Sengupta N prepared the final version of the manuscript. Marshall AL, Ham S, and Tapper E provided critical review

© 2018 by the AGA Institute

< Previous Article

Articles in Press

Next Article >

Copyright © 2018 Elsevier Inc. All rights reserved. | Privacy Policy | Terms & Conditions | Use of Cookies | About Us | Help & Contact | Accessibility The content on this site is intended for health professionals.

Advertisements on this site do not constitute a guarantee or endorsement by the journal, Association, or publisher of the quality or value of such product or of the claims made for it by its manufacturer.